Potential biotech collaboration between India and Colombia

Biosimilars/General | Posted 15/10/2021 post-comment0 Post your comment

A letter of intent on cooperation in biotechnology has been signed between India and Colombia, which could include collaborations on vaccines, biosimilars, and medical devices.

Shaking hands V13D29

On 2 October 2021, a letter of intent on cooperation in biotechnology was signed between the Governments of India (Department of Biotechnology, Ministry of Science and Technology) and Colombia (Ministry of Science, Technology and Innovation).

The meeting, which was attended by Marta Lucía Ramírez de Rincon, Vice President and Minister of Foreign Affairs of the Republic of Colombia, and External Affairs Minister for India, Dr S Jaishankar, included discussion of cooperation on vaccines, biosimilars and medical devices.

The collaboration could help the Indian biotechnology industry achieve its aims of reaching a US$150 billion bioeconomy by 2025, according to Renu Swarup, head of the Department of Biotechnology in India, while Vice President of Colombia Marta Lucía Ramírez de Rincon declared the health and biotechnology sectors ‘important priority areas of common interest’.

Colombia’s Minister of Health and Social Protection, Fernando Ruiz Gomez, noted India’s reputation as a worldwide vaccine manufacturing centre while the country’s Vice Minister of Science, Technology and Innovation, Sergio Cristancho, said Colombia hoped to ‘replicate Indian models of knowledge generation’ and was looking forward to creating long-term collaborations with the country.

In 2020, Colombia approved its first producto bioterapéutico similar (similar biotherapeutic product) for adalimumab, in the form of Amgevita (ABP 501, Amgen) [1].

The potential collaboration follows news of a partnership between health authorities in the EU and Brazil, allowing the two authorities to exchange sensitive information about medicines [2].

Related articles
Regulatory landscape for similar biotherapeutic products in Latin America

Merck partners with Indian drugmakers to increase access to COVID-19 drug

The biosimilars market in Latin America: a summary


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Posible colaboración biotecnológica entre India y Colombia

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Posible colaboración biotecnológica entre India y Colombia

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. GaBI Online - Generics and Biosimilars Initiative. Amgevita approved in Colombia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 15]. Available from: www.gabionline.net/biosimilars/news/Amgevita-approved-in-Colombia
2. GaBI Online - Generics and Biosimilars Initiative. EU and Brazil health authorities enter partnership [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Oct 15]. Available from: www.gabionline.net/policies-legislation/EU-and-Brazil-health-authorities-enter-partnership

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Department of Biotechnology, Government of India; Ministry of Science, Technology and Innovation, Government of Colombia

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010